Genmab A/S News

News

0

Ticker

GMAB.CO

ISIN

DK0010272202

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Genmab A/S Eulerpool News

9/30/2025, 12:42:06 AM

Optimismus an der Wall Street trotz bevorstehender Herausforderungen

9/29/2025, 9:45:54 PM

Nach dem Sturm folgt Sonnenschein: Nasdaq erholt sich trotz bevorstehendem "Shutdown"

9/29/2025, 5:37:06 PM

Technologie-Aktien trotzen politischen Unsicherheiten – Nasdaq erholt sich mit deutlichem Plus

9/29/2025, 4:36:35 PM

Börsenstart mit Potenzial: US-Märkte trotzen drohendem Shutdown

9/29/2025, 12:58:28 PM

Europäische Börsen zeigen sich robust zu Wochenbeginn

9/29/2025, 12:23:04 PM

Genmab plant milliardenschweren Kauf von Merus: Strategische Weichenstellung im Biotech-Bereich

9/26/2025, 12:45:00 PM

Pharma-Märkte in Aufruhr: Trumps Zolllast und die globalen Reaktionen

Pharmaceutical Markets in Turmoil: Trump's Tariff Burden and Global Reactions

4/1/2025, 12:21:09 PM

Europäische Aktienmärkte im Aufwind: Vorsichtiger Optimismus trotz positiver Impulse

12/24/2024, 9:45:42 AM

Warum größer nicht immer besser ist: Die versteckte Krise der Biotech-Branche

Why Bigger Isn't Always Better: The Hidden Crisis of the Biotech Industry

12/17/2024, 3:54:11 PM

Dänemark im Arbeitstakt: Novo Nordisks Einfluss auf den Arbeitsmarkt

Denmark in the Work Rhythm: Novo Nordisk's Impact on the Labor Market

12/9/2024, 3:40:55 AM

Innovative Fortschritte in der Therapie des Multiplen Myeloms: Vielversprechende Ergebnisse für Daratumumab-Kombinationen

Innovative Advances in the Treatment of Multiple Myeloma: Promising Results for Daratumumab Combinations

12/8/2024, 11:15:31 PM

Neue Hoffnung für Multiple-Myelom-Patienten: TECVAYLI punktet in klinischer Studie

New Hope for Multiple Myeloma Patients: TECVAYLI Scores in Clinical Trial

12/8/2024, 7:52:05 PM

Revolution in der Behandlung von schwelendem multiplem Myelom: Frühe Intervention zeigt Erfolg

Revolution in the Treatment of Smoldering Multiple Myeloma: Early Intervention Shows Success

10/10/2024, 7:25:48 PM

FDA verleiht wegweisenden Status für Biogens Nierentransplantations-Therapie

FDA Grants Breakthrough Status for Biogen's Kidney Transplant Therapy

8/5/2024, 7:37:26 PM

BioNTech zieht sich aus PD-L1-Entwicklung mit Genmab zurück und meldet Quartalsverluste

BioNTech withdraws from PD-L1 development with Genmab and reports quarterly losses

Genmab A/S Stock News

Genmab A/S is being monitored by journalists and investors worldwide. We gather the latest Genmab A/S news here.

March 18·
Yahoo
Genmab A/S Touts Strong 2025, Teases Catalyst-Heavy 2026 With Potential 2027 Launches
March 18·
Yahoo
Genmab A/S Teases 2026 Wave of Registrational Readouts for EPKINLY, Rina-S and Petosemtamab
March 16·
Yahoo
Completion of Share Buy-back Program
March 11·
SeekingAlpha
Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
March 11·
SeekingAlpha
Harbor Health Care ETF Q4 2025 Portfolio Review
March 9·
Yahoo
Transactions in Connection with Share Buy-back Program
March 5·
ChartMill
Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case
March 3·
Yahoo
How The Genmab (CPSE:GMAB) Narrative Is Shifting As 2026 Catalyst Risks Build
March 2·
Yahoo
Correction to Company Announcement No. 13 of March 2, 2026
March 2·
Yahoo
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
March 2·
Yahoo
Netflix upgraded, Pinterest downgraded: Wall Street's top analyst calls
March 2·
Yahoo
Here Are Monday’s Top Wall Street Analyst Research Calls: AppLovin, Blue Owl Capital, CrowdStrike, Dutch Bros., Jet Blue, Novo Nordisk, PayPal, Twilio, and More
March 2·
Benzinga
Wells Fargo Initiates Coverage On Genmab with Overweight Rating, Announces Price Target of $40
February 28·
Yahoo
Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Weakness
February 28·
Yahoo
Is Genmab (CPSE:GMAB) Pricing Look Attractive After Recent Share Price Weakness
February 27·
Yahoo
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
February 25·
Yahoo
Genmab to Participate in Upcoming Investor Conferences
February 24·
Yahoo
Capital Increase in Genmab as a Result of Employee Warrant Exercise
February 24·
Yahoo
Bolt Biotherapeutics to Participate in Upcoming March Conferences
February 24·
Yahoo
Genmab Buyback And Abkinley Approval Reframe Growth And Risk Balance

Genmab A/S Stock Press Releases

Genmab A/S regularly publishes news on the company's website that are relevant for investors.

December 13•
Genmab A/S
Genmab Says Janssen Receives Conditional European Marketing Authorization For Rybrevant
November 4•
Genmab A/S
Genmab Improves Its 2021 Financial Guidance
September 19•
Genmab A/S
Genmab Present Interim Results From Study For Tisotumab Vedotin Combination Therapy Treatment Of Recurrent/Metastatic Cervical Cancer
September 9•
Genmab A/S
Genmab: Clinical Trial On Epcoritamab Published In Lancet
August 11•
Genmab A/S
Genmab Q2 EBIT Down At DKK 787 Mln
July 21•
Genmab A/S
Genmab Reports Net Sales Of Darzalex In Q2 At $1,433 Mln
July 1•
Genmab A/S
Genmab Completes Share Buy-Back Program
June 22•
Genmab A/S
Genmab Announces That Janssen Has Received European Marketing Authorizations For Darzalex
May 21•
Genmab A/S
Genmab: Janssen Gets Positive CHMP Opinion Recommending Darzalex Subcutaneous Formulation For Patients With Light-Chain Amyloidosis
May 5•
Genmab A/S
Genmab Q1 Net Profit at DKK 1,096 Million
April 20•
Genmab A/S
Genmab: Net Sales Of Darzalex® In Q1 Of 2021 Totaled USD 1,365 Million
April 9•
Genmab A/S
Genmab And Seagen Say FDA Has Accepted for Priority Review the BLA seeking accelerated approval for Cervical Cancer drug
April 9•
Genmab A/S
Genmab Announces U.S. FDA Filing Acceptance For Priority Review Of Tisotumab Vedotin Biologics License Application
March 30•
Genmab A/S
Genmab Gets European Marketing Authorization For Kesimpta In Relapsing Multiple Sclerosis
February 23•
Genmab A/S
Genmab Initiates Share Buy-Back Program
February 23•
Genmab A/S
Genmab FY Operating Profit At DKK 6,313 Mln, Above Expectations
February 22•
Genmab A/S
Genmab Appoints Of Tahamtan Ahmadi Chief Medical Officer, Head Of Experimental Medicines
February 10•
Genmab A/S
Genmab And Seagen Submit Tisotumab Vedotin Biologics License Application To The U.S. FDA For Patients With Recurrent Or Metastatic Cervical Cancer
February 10•
Genmab A/S
Seagen And Genmab Submit Tisotumab Vedotin Biologics License Application To The U.S. FDA For Patients With Recurrent Or Metastatic Cervical Cancer
February 1•
Genmab A/S
Genmab: CHMP Issues Positive Opinion Recommending Ofatumumab
January 26•
Genmab A/S
Genmab Announces 2020 Net Sales Of Darzalex
January 26•
Genmab A/S
Genmab Net Sales Of Darzalex In 2020 Totaled USD 4,190 Million
January 15•
Genmab A/S
Genmab Says U.S. FDA Approves Amyloidosis Treatment Drug
November 24•
Genmab A/S
Genmab Announces Enapotamab Vedotin Update
November 5•
Genmab A/S
Genmab: Janssen Submits Type II Variation Application To European Medicines Agency
November 4•
Genmab A/S
Genmab Q3 Operating Profit Up At DKK 858 Mln
October 21•
Genmab A/S
Genmab Announces IFM, Hovon And Janssen Achieve Positive Topline Results In Second Part Of Phase 3 Cassiopeia Study Of Daratumumab In Multiple Myeloma At Pre-Planned Interim Analysis
September 22•
Genmab A/S
Genmab Commences Binding Arbitration Of Two Matters Under License Agreement With Janssen
September 10•
Genmab A/S
Genmab: Janssen Submitted Supplemental Biologics License Application To U.S. FDA
August 20•
Genmab A/S
U.S. FDA Approves Kesimpta In Relapsing Multiple Sclerosis

Genmab A/S News 2026

This page contains all current news, analysis and press releases for Genmab A/S stock (GMAB.CO, ISIN: DK0010272202). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Genmab A/S.

Genmab A/S Stock

Genmab A/S Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark.